Monitoring the Entire Patient Journey

Because changing patient conditions should not be a surprise

There is a Blind Spot in Chronic Disease Management

Continuous perfusion monitoring may complete the picture

Basic non-invasive vital signs do not provide a full picture of patient health, requiring clinicians to use more invasive diagnostic methods such as right heart catheterization and blood samples to assess cardiovascular performance. Tissue oximetry, a direct measurement of tissue perfusion, may address gaps in patient data and identify advancing cardiac conditions earlier than other techniques, helping prevent late diagnoses and the need for invasive interventions.

Envello is developing non-invasive sensors to monitor advanced biometrics

Legacy perfusion monitors are bulky and lack scalability for high-volume patient monitoring. Envello devices can be used on multiple areas of the body – including the chest, limbs, or forehead – providing continuous monitoring of tissue oximetry with a single light-weight sensor in any clinical setting.
‍
These statements have not been evaluated by the U.S. Food and Drug Administration (FDA).

Meet Envello Core

Building a Scalable Solution for ALL Clinical Settings

Envello Core is just the beginning. We are developing a full suite of multi-modal hemodynamic profiling sensors for improved monitoring of cardiovascular performance, which will help empower many HCPs with early detection and potentially life saving technology.

Lean more about our pipeline
Regional hospitals
In Transport
In The ER
CVICU
Step Down Units
Regional hospitals
In Transport
In The ER
CVICU
Step Down Units

Leveraging Engineering Excellence

Envello is a unique commercial-stage startup that is a subsidiary of NIRSense, a pioneering medical device company founded in 2018 that was contracted by the Department of Defense to protect the health of U.S. warfighters. Leveraging in-house engineering expertise, Envello is focused on the design, development and commercialization of innovative technologies that have been de-risked with over $28M in U.S. military funding. Cardiovascular disease is the leading cause of civilian mortality and Envello’s technology is taking aim at improving patient outcomes while reducing footprint and costs.

Lean more about Envello

Collaborating with Leading Research Organizations

We have key partnerships with several of the industry’s leading researchers and institutions to ensure we are building clinically effective, safe, and affordable solutions.

Interested in Research, Collaboration, or Investment?

 As Envello enters a phase of rapid growth, we are interested in strategic partners who share our vision and goals to help expand our reach and bring our groundbreaking monitoring solutions to patients worldwide. If you are interested in collaborating, please fill out the below form and our team will get in touch with you soon.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Collaborating with Leading Research Organizations

We have key partnerships with several of the industry’s leading researchers and institutions to ensure we are building clinically effective, safe, and affordable solutions.

Collaborating with Leading Research Organizations

We have key partnerships with several of the industry’s leading researchers and institutions to ensure we are building clinically effective, safe, and affordable solutions.